CritiTech Moves Into New North Lawrence, Kansas, Headquarters
09/16/2013
“We are very excited about our new home,” said Matthew McClorey, CritiTech’s COO. “Due to the growth the company has experienced over the past year, we needed more space to accommodate our growing laboratory and forthcoming API manufacturing operations.”
CritiTech’s focus at its new facility will be using its proprietary fine-particle drug development and production technology to help its customers develop new, improved and differentiated human and animal pharmaceutical drugs. CritiTech expects to use the manufacturing space in its facility to produce API for clients as they advance their drugs from the research and development stage through Phase I and Phase II clinical trials.
“Our target is to be operating in a FDA-regulated, cGMP compliant environment later this year,” said Gary Clapp, vice president of Technical Operations. “The new facility has been very helpful in showcasing our resources and expertise in fine particle drug development. The new laboratories, analytical equipment and manufacturing capabilities have impressed potential clients, customers and strategic partners. They can now see CritiTech has completed the transition from an R&D company to one that is ready to work hands on with them to develop and produce fine particle drugs that have a competitive advantage and distinct value proposition.”
Most Read
-
-
2019 Top States for Doing Business: Georgia Ranks #1 Sixth Year in a Row
Q3 2019
-
A Site Selector’s Checklist for Locating in the U.S.
Location USA 2019
-
Hot Jobs: Growing Industrial Sectors
Q4 2019
-
Where to Invest in the Booming Aerospace Manufacturing Industry
2019 Auto/Aero Site Guide
-
What Should High-Growth Companies Look for in a Community?
Q4 2019
-
A Tale of Demographics
Q4 2019